TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02413723

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Videolaryngoscope
Description: McGrath Mac videolaryngoscope will be use for first attempt of intratracheal intubation.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard laryngoscope
Description: Macintosh laryngoscope will be use for first attempt of intratracheal intubation.
Study: NCT00883402

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CEA, CAS
Description: Carotid Artery Stenting (CAS) Carotid endarterectomy (CEA)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CEA, CAS
Description: Carotid Artery Stenting (CAS) Carotid endarterectomy (CEA)
Study: NCT01519700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP2006
Description: Eligible patients will be teated with EP2006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Eligible patients will be teated with Filgrastim
Study: NCT01024270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Study: NCT01774734

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical therapy
Description: Physical therapy~* Provided by 2 experienced physiotherapist~* Applied to every patients 3 times weekly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Physical therapy~* Provided by 2 experienced physiotherapist~* Applied to every patients 3 times weekly

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neck Strength Exerciser (NSE)
Description: * Neck strength exerciser use 10-20 minutes daily at home~* Plus traditional physical therapy three times weekly provided by two experienced physical therapist
Study: NCT02553486

Intervention type: OTHER
Intervention: quality of life evaluation
Study: NCT03348358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rhythmic music
Description: playing rhythmic music during labor

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: No music during labor
Study: NCT01399242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Certican
Description: Patients' therapy will be replaced from tacrolimus-based to everolimus-based immunosuppression. Everolimus will be introduced on day 1 at dose of 2 mg/day (1mg bid), and then everolimus trough levels will be obtained from day 3 onwards until C0 reaches the target for three consecutive days. Through levels will be adjusted to achieve 6-10ng/ml. Thereafter, if the target level was reached, the measurement will be performed weekly for 4 weeks and every 2 weeks until 8 weeks after conversion.In parallel, the tacrolimus dose will be reduced by 50% on day 1 and another 25% on day 7. The Tacrolimus will be withdrawn on day 14 if the target levels of everolimus are obtained.EC-MPS will be unchanged until day 14 after conversion.
Study: NCT02389504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Exertional Physical Therapy
Description: By contrast, the dynamic exertion protocol includes the treadmill running aspect, but also incorporates other exercises that involve lateral movement (e.g., side lunges, lateral speed training exercises) as well as planar changes (e.g., burpees, squat thrusts) . Recovery on these exercises is measured based on time subjects are able to tolerate the exertion without symptom increase. Across all exertion protocols additional measures of subjective physical effort and objective measurement of heart rate are taken.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Exertional Physical Therapy
Description: Standard treadmill running, monitoring heart rate
Study: NCT01783951

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK
Description: Patients will be receive DC-CIK cell therapy at days 15, 17 and 19 per cycle and received cycles of treatment once every 21 days.
Study: NCT01514201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT01783951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: The dose of S-1 is determined according to the body surface area as follows: \<1.25 m2, 40 mg; 1.25 to \<1.5 m2, 50 mg; and ≥1.5 m2, 60 mg, given twice daily after meals for 14 days followed by 7 days rest.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: The dose of S-1 is determined according to the body surface area as follows: \<1.25 m2, 40 mg; 1.25 to \<1.5 m2, 50 mg; and ≥1.5 m2, 60 mg, given twice daily after meals for 14 days followed by 7 days rest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is administered at 75 mg/m2 intravenously over 1 to 3 hours every 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin is administered at 75 mg/m2 intravenously over 1 to 3 hours every 21 days.
Study: NCT00389116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gastrograffin
Description: ingestion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: water
Description: oral water ingestion
Study: NCT01112293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC1008
Description: GC1008 is a human IgG4 kappa monoclonal antibody capable of neutralizing all mammalian isoforms of TGFbeta (i.e., beta1, beta 2 and beta 3). GC1008 is a high affinity antibody with dissociation constants (Kds) of 1.8 nM, 2.8 nM and 1.4 nM for TGF1,2,and 3, respectively.
Study: NCT02838212

Intervention type: DRUG
Intervention: adverse drug reaction
Description: drug-related death
Study: NCT06321874

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygen
Study: NCT04226482

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: New Device
Description: Laparoscopic appendectomy using new ultrasonic shears.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Used Device
Description: Laparoscopic appendectomy using reprocessed ultrasonic shears.
Study: NCT01807052

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04477577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New Parent Intervention
Description: This arm will receive the Obstetric and Pediatric primary care provided within MGH obstetric and pediatric primary care practices, with additional active and targeted engagement of new parents by a health coach.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety Control
Description: This arm will receive the Obstetric and Pediatric primary care provided within MGH obstetric and pediatric primary care practices, with additional infant safety education materials.
Study: NCT00917761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir and peginterferon (Pegasys) (52 weeks)
Description: Entecavir 0.5 mg/day po at week 1-4 Peginterferon alfa-2a 180 ug/week sc at week 5-52
Study: NCT01185873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: Repeated oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Repeated oral doses
Study: NCT00855088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir
Description: Healthy male volunteers will take darunavir 600 mg orally twice daily for 15 doses (8 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Healthy male volunteers will take ritonavir 100 mg orally twice daily for 15 doses (8 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine
Description: Healthy male volunteers will take etravirine 200 mg orally twice daily for 15 doses (8 days)
Study: NCT02767427

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Wipes
Description: (Standard of Care) Chlorhexidine wipes are a commonly used pre-operative skin cleansing measure, designed to reduce bacterial load on the skin of the surgical site.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: Chlorhexidine wipes will not be used though it is a commonly used pre-operative skin cleansing measure.
Study: NCT02885155

Intervention type: OTHER
Intervention: Echocardiography
Description: planned at regular intervals

Intervention type: OTHER
Intervention: Hemodynamic examinations (right cardiac catheterization)
Description: planned at regular intervals
Study: NCT01544530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold isotonic fluid and central venous hypothermia catheter
Description: 20-30ml/kg of isotonic crystalloid resuscitation fluid will be used for induction. Hypothermia (32-33 degrees C) will be sustained until organ procurement using an FDA approved central venous catheter connected to an external temperature regulating system
Study: NCT00917761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon (Pegasys) (96 weeks)
Description: Peginterferon alfa-2a 180 ug/week sc at week 1-96
Study: NCT05510869

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bimanual 1.4 mm microincision cataract surgery (B-MICS) with IOL implantation in a wound-assisted technique. In bimanual MICS group a self-sealing 1.4 mm wide incision was created supratemporally
Description: microincision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch \& Lomb

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coaxial 1.8 mm microincision cataract surgery (C-MICS) with IOL implantation with an injector through the 1.8 mm wide incision created temporally.
Description: microincision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch \& Lomb

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coaxial 2.4 mm small incision cataract surgery (C-SICS) with IOL implantation with an injector through the 2.4 mm wide incision located temporally.
Description: small incision cataract surgery (phacoemulsification) with implantation of a foldable, acrylic, hydrophilic IOL Incise® MJ14, Bausch \& Lomb
Study: NCT03062475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle intervention with dietary and exercise recommendation
Description: With the dietary intervention we aimed to promote a healthy pattern of eating but not necessarily to restrict energy intake.For example we suggested exchanging carbohydrate-rich foods with a medium-to-high glycaemic index for those with a lower glycaemic index to reduce the glycaemic load, and restricting dietary intake of saturated fat.~With respect to advice on physical activity, we focused on incremental increases in walking from a pedometer assessed, or encourage them to do moderate cycling during pregnancy.
Study: NCT00633191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-pseudomonas IgY gargle
Description: Gargle (solution), \> 5FKU, every night after toothbrushing, life-long
Study: NCT02101502

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questioner
Description: Obstetrics and gynecology health problems questionnaire for patients Educational effectiveness special questionnaire for medical staffs Institutional capacity special questionnaire for institution employees

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questioner
Description: Obstetrics and gynecology health problems questionnaire for patients Educational effectiveness special questionnaire for medical staffs Institutional capacity special questionnaire for institution employees

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questioner
Description: Obstetrics and gynecology health problems questionnaire for patients Educational effectiveness special questionnaire for medical staffs Institutional capacity special questionnaire for institution employees
Study: NCT03602937

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Renastep
Description: Renastep is a ready-to-use, high energy, low volume liquid renal specific feed that can be administered enterally via tube or oral consumption.
Study: NCT04067284

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition education
Description: Nutrition Education on~* Continued breastfeeding until two years of age~* Food groups~* Balanced diet~* Introduction to locally available nutritious and low-cost foods~* Amount and frequency of complementary feeding~* Safe water, and~* Handwashing with soap before feeding

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Homemade yogurt supplementation
Description: The homemade yogurt supplementation will start a week after beginning of 6 months of age once the child is introduced to solid foods of the mother's choice. The yogurt will be supplied to the mothers every day at time of feeding.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: No intervention/ control group
Study: NCT03522181

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline
Study: NCT00917761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon (Pegasys) (48 weeks)
Description: Peginterferon alfa-2a 180 ug/week sc at week 1-48
Study: NCT01520376

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counselling
Description: Visit by a psychiatrist at day-30 and day-180 after discarge
Study: NCT02936466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bipolife® group
Description: The participant is proposed to play to the serious game Bipolife® with following instructions :~* At least one connection per week during 4 weeks~* Connection time is free On add on of usual treatment After the 4 weeks and the first visit (V1), the participant can continue to participate to the serious game as much as he wishes, without any specific instructions.~After connecting to the site www.bipolar.ubi.com, the participant is proposed to create his avatar and conduct him on his house. He realizes different kind of daily actions (like sleeping, sport activity, cooking) ; every action lead to win or to loose energy and mood points. The final aim is to stabilize the avatar's mood. Thanks to this experience, the participant can learn to distinguish positive and negative actions impacting on his condition.
Study: NCT01441882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01758913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: To compare the efficacy, the side effects and the renal prostaglandin (PG) excretion between indomethacin and ibuprofen in extremely low birth weight (ELBW) infants.
Study: NCT02988830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subcutaneous Electric Lumbar Stimulation
Study: NCT03471507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bonipar
Description: Apply 2 pumps 2 times a day to be applied topically on the affected area during a two week treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac sodium topical solution 1.5%
Description: Apply 2 pumps 2 times a day to be applied topically on the affected area during a two week treatment period.
Study: NCT03421873

Intervention type: OTHER
Intervention: 0h/1h hs-cTnT protocol
Description: Implementation of a 0h/1h hs-cTnT protocol in routine care
Study: NCT02652351

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells
Description: A single dose of 2×107 hUC-MSC will be implanted to patients by intravenous infusion or Hepatic artery intervention, and repeated every week for four times.
Study: NCT02489292

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HepaStem
Description: HepaStem will be administered in maximum 4 infusion days, spread over an 8-week period with an interval of 2 to 3 weeks between infusion days. The target total dose of cells will be 50x10E6 cells/kg body weight
Study: NCT00828763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14c}-GSK1349572
Description: HIV-Integrase inhibitor labelled with a carbon 14 marker
Study: NCT00300313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10 to 20 mg / day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1-2 capsules
Study: NCT03018639

Intervention type: BEHAVIORAL
Intervention: Dialectical Behavior Therapy
Description: DBT is a cognitive-behavioral treatment program that was developed to treat suicidal Patients with BPD (Linehan, 1993).
Study: NCT03078894

Intervention type: DIAGNOSTIC_TEST
Intervention: Zika
Description: Zika Diagnostic test

Intervention type: DIAGNOSTIC_TEST
Intervention: Zika
Description: Zika Diagnostic test

Intervention type: DIAGNOSTIC_TEST
Intervention: Chikagunya
Description: Chikagunya Diagnostic test

Intervention type: DIAGNOSTIC_TEST
Intervention: Chikagunya
Description: Chikagunya Diagnostic test

Intervention type: DIAGNOSTIC_TEST
Intervention: Dengue
Description: Dengue Diagnostic test

Intervention type: DIAGNOSTIC_TEST
Intervention: Dengue
Description: Dengue Diagnostic test
Study: NCT04355546

Intervention type: OTHER
Intervention: Non-interventional
Description: As this is a Non-interventional trial, only data obtained within the current routine management of COPD at outpatient respiratory centres or GP centres will be documented.
Study: NCT01389869

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sniffing emotional tears
Description: A band-aid soaked 100μl of emotional tears will be applied just below nostrils.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sniffing trickled saline
Description: A band-aid soaked 100μl of trickled saline will be applied just below nostrils.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sniffing fasting plasma
Description: A band-aid soaked 100μl of own fasting plasma will be applied just below nostrils.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sniffing postprandial plasma
Description: A band-aid soaked 100μl of own postprandial plasma will be applied just below nostrils.
Study: NCT01804881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Six week program to address problematic eating

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle counseling
Description: Six week program to address problematic eating
Study: NCT02316496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: cetuximab 500mg/m²/ IV infusion, (q2w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 180mg/m², in 500ml NaCl 0.9% solution, 90 min IV infusion (q2w)
Study: NCT03261219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrapulmonary Percussive ventilation
Description: mode of airway clearance using mouthpiece and alternating air currents applied directly to the airway

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chest Physiotherapy Vest (Incourage)
Description: mode of airway clearance using external vibratory vest
Study: NCT00546546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: early immunosuppressants (azathioprine, methotrexate)
Description: azathioprine 2.5 mg/kg/day SC methotrexate 25 mg/week if aza not tolerated
Study: NCT02569684

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotic fibers: oligofructose and inulin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Study: NCT01770171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Carboplatin AUC 5+ Paclitaxel 175 mg/mq+Bevacizumab 15 mg/kg q 21 for 6 -8 cycles + Bevacizumab 15 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
Description: Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
Study: NCT02862873

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Spinal anaesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Study: NCT00836186

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation therapy
Description: Patients will receive whole breast radiation therapy at a dose of 180-200 centigray (cGy) per fraction for 23-27 fractions to a total dose of 4600 - 4860 cGy. Additional radiation to the lumpectomy bed (Boost) is at the discretion of the treating physician. The total dose to the tumor bed cannot exceed 6600 cGy.
Study: NCT02977858

Intervention type: OTHER
Intervention: Educational practice for HCPs,Dissemination only
Description: Study participants are health care professionals (HCPs) who will be provided educational material and complete knowledge assessments

Intervention type: OTHER
Intervention: Educational practice for HCPs,Dissemination only
Description: Study participants are health care professionals (HCPs) who will be provided educational material and complete knowledge assessments

Intervention type: OTHER
Intervention: Educational practice for HCPs,Spaced Education
Description: Study participants are health care professionals (HCPs) who will be provided educational material via a Spaced Education program; participants will subsequently complete knowledge assessments
Study: NCT03522181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin
Study: NCT03606473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Description: is used to stimulate dopamine release in the brain
Study: NCT01133691

Intervention type: DIETARY_SUPPLEMENT
Intervention: clear fluid, light breakfast
Description: clear fluid 7 ml/kg, breakfast consisting of yoghurt, muesli, mild
Study: NCT01972672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icaritin
Description: Icaritin 600 mg orally, twice daily for a total daily dose of 1200 mg
Study: NCT03142880

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric ropivacaine
Description: We change the density of ropivacaine solution to make it into an marginally hyperbaric state or into an commonly hyperbaric state.and we hypothesized that the marginally hyperbaric ropivacaine will get a similar efficacy to commonly hyperbaric solutions but a more steadily hemodynamic status.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: hyperbaric ropivacaine
Description: We change the density of ropivacaine solution to make it into an marginally hyperbaric state or into an commonly hyperbaric state.and we hypothesized that the marginally hyperbaric ropivacaine will get a similar efficacy to commonly hyperbaric solutions but a more steadily hemodynamic status.